A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Type of Cancer
Head and Neck
Locations
Hackensack
Sponsor
Merck
Protocol Number
Merck MK-3475-048
Cancer Diagnosis
To Learn More Call
201-510-0910